JP2023527054A5 - - Google Patents
Info
- Publication number
- JP2023527054A5 JP2023527054A5 JP2022572765A JP2022572765A JP2023527054A5 JP 2023527054 A5 JP2023527054 A5 JP 2023527054A5 JP 2022572765 A JP2022572765 A JP 2022572765A JP 2022572765 A JP2022572765 A JP 2022572765A JP 2023527054 A5 JP2023527054 A5 JP 2023527054A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amino acid
- seq
- composition according
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063031854P | 2020-05-29 | 2020-05-29 | |
| US63/031,854 | 2020-05-29 | ||
| PCT/EP2021/064312 WO2021239928A2 (en) | 2020-05-29 | 2021-05-28 | Treatment of cardiometabolic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527054A JP2023527054A (ja) | 2023-06-26 |
| JP2023527054A5 true JP2023527054A5 (cg-RX-API-DMAC10.html) | 2024-05-30 |
Family
ID=76269736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572765A Pending JP2023527054A (ja) | 2020-05-29 | 2021-05-28 | Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12410254B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4157873A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023527054A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230018446A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115667309A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021279277A1 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112022023438A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3183611A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL298299A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021239928A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202237647A (zh) * | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| KR20230110304A (ko) * | 2020-11-18 | 2023-07-21 | 아스트라제네카 아베 | 스테로이드 절약 |
| TW202317617A (zh) * | 2021-04-23 | 2023-05-01 | 瑞典商阿斯特捷利康公司 | 皮膚紅斑狼瘡之治療 |
| SMT202300382T1 (it) | 2021-04-23 | 2024-01-10 | Astrazeneca Ab | Regime di dosaggio anti-ifnar1 per iniezione sottocutanea |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003087339A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for pulmonary administration |
| EP1494651A4 (en) | 2002-04-11 | 2010-10-13 | Medimmune Vaccines Inc | PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM |
| JP2006512102A (ja) | 2002-04-11 | 2006-04-13 | メディミューン・ヴァクシンズ・インコーポレーテッド | 噴霧乾燥による生物活性材料の防腐 |
| US20040042972A1 (en) | 2002-04-11 | 2004-03-04 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| KR20050088175A (ko) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | 생물활성 물질의 고압 분무 건조 |
| NZ545314A (en) * | 2003-08-04 | 2009-03-31 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| ES2643237T3 (es) | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
| MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| SMT201700063T1 (it) | 2009-09-03 | 2017-03-08 | Medimmune Llc | Diagnosi di interferoni di tipo 1 |
| CN107110939B (zh) * | 2014-09-11 | 2021-05-14 | 力保科学公司 | 用于测定心血管疾病或事件的风险参数的系统 |
| SI3769781T1 (sl) | 2015-08-19 | 2023-06-30 | Astrazeneca Ab | Stabilna formulacija proti-IFNAR1 |
| FI20177098A1 (fi) * | 2017-08-29 | 2019-03-01 | Leppaeluoto Juhani | Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen |
| SG11202101946YA (en) * | 2018-09-18 | 2021-04-29 | I Mab Biopharma Hangzhou Co Ltd | Anti-ifnar1 antibodies for treating autoimmune diseases |
| EP3881233A4 (en) * | 2018-11-15 | 2022-11-23 | Ampel Biosolutions, LLC | DISEASE PREDICTION AND TREATMENT PRIORIZATION WITH MACHINE LEARNING |
-
2021
- 2021-05-28 JP JP2022572765A patent/JP2023527054A/ja active Pending
- 2021-05-28 CA CA3183611A patent/CA3183611A1/en active Pending
- 2021-05-28 CN CN202180037656.9A patent/CN115667309A/zh active Pending
- 2021-05-28 AU AU2021279277A patent/AU2021279277A1/en not_active Abandoned
- 2021-05-28 WO PCT/EP2021/064312 patent/WO2021239928A2/en not_active Ceased
- 2021-05-28 EP EP21729861.1A patent/EP4157873A2/en not_active Withdrawn
- 2021-05-28 IL IL298299A patent/IL298299A/en unknown
- 2021-05-28 EP EP24220273.7A patent/EP4566667A3/en not_active Withdrawn
- 2021-05-28 BR BR112022023438A patent/BR112022023438A2/pt unknown
- 2021-05-28 KR KR1020227045818A patent/KR20230018446A/ko not_active Ceased
-
2023
- 2023-12-22 US US18/394,365 patent/US12410254B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9783589B2 (en) | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases | |
| Billiau et al. | Anti‐interferon‐γ antibody protects mice against the generalized Shwartzman reaction | |
| AU2019279946A1 (en) | Methods for treating atopic dermatitis by administering an IL-4R antagonist | |
| RU2587620C2 (ru) | Способы лечения аутоиммунных заболеваний антагонистами dll4 | |
| CN103458926A (zh) | 改进的高浓度抗TNF α 抗体液体制剂 | |
| KR20170135967A (ko) | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 | |
| JP7045327B2 (ja) | 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン | |
| WO2012027328A2 (en) | Anti-ox40 antibodies and methods of using the same | |
| JP2022169504A5 (cg-RX-API-DMAC10.html) | ||
| JP2024524159A5 (cg-RX-API-DMAC10.html) | ||
| CN104105505A (zh) | 用于治疗类风湿性关节炎的组合物及其使用方法 | |
| FI4358995T3 (fi) | Mystostatiinireitin estäjä yhdessä glp-1-reitin aktivaattorin kanssa käytettäviksi metabolisten häiriöiden hoidossa | |
| KR20230044312A (ko) | 보체 매개된 질환을 갖는 대상체의 염증성 시토카인 및 피로 | |
| MX2013003920A (es) | Metodos para el tratamiento de la psoriasis. | |
| JP7645555B2 (ja) | Ｐｄ－ｌ１タンパク質が含まれた融合タンパク質およびその用途 | |
| JP2022542035A (ja) | 抗ｐｒｅ－ｓ１ ｈｂｖ抗体を用いるｈｂｖ感染症の治療方法 | |
| JP2022545312A5 (cg-RX-API-DMAC10.html) | ||
| JP2024116343A (ja) | ヘパピティスｂウイルス複製およびヘパピティスｂウイルス表面抗原分泌の抑制方法 | |
| AU2005232653B2 (en) | Methods of treating autoimmune and inflammatory diseases | |
| JP2022534494A5 (cg-RX-API-DMAC10.html) | ||
| JP2022527542A5 (cg-RX-API-DMAC10.html) | ||
| AU2023312911A1 (en) | Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein | |
| CN108992671B (zh) | 一种药物组合物及其制备治疗肝损伤的药物中的用途 | |
| WO2012097288A1 (en) | Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor | |
| CN114901313A (zh) | 急性期的视神经脊髓炎的预防或治疗剂 |